Bixiye
QP32-17 Pharmacy Benefit Update - Dispense as Written (DAW) 1 Clarification
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2017
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 3071 - 3080 ee natiijooyinka 3273
Bixiye
P55-17 Prior Authorization Requirement for Orthognathic Surgery
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2017
Bixiye
P54-17 Clarification to Commercial Prior Authorization Requirements for Early Intensive Behavioral Intervention (EIBI)
Taariikhda uu dhaqangalayo barnaamijka: Okt 10, 2017
Bixiye
P53-17 New Drug-Related Prior Authorization Requirements for Edaravone (Radicava) and Cerliponase Alfa (Brineura)
Taariikhda uu dhaqangalayo barnaamijka: Okt 10, 2017
Bixiye
QP31-17 New Pre-Authorization Form for Infliximab
Taariikhda uu dhaqangalayo barnaamijka: Okt 05, 2017
Bixiye
P52-17 New Drug-Related Prior Authorization with Quantity Limit Criteria: Parathyroid Hormone Analog for Osteoporosis
Taariikhda uu dhaqangalayo barnaamijka: Okt 03, 2017
Bixiye
QP30-17 Disclosure of Ownership Form
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 25, 2017
Bixiye
P49-17 Two New Medicare Advantage Prescription Drug Products in 2018
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 25, 2017
Bixiye
P50-17 Provider Data Accuracy and Identified Lack of Claim Submissions
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 25, 2017
Bixiye
QP29-17 Pharmacy Benefit Exclusion for Kymriah
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 21, 2017